ePrints

Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma

Lookup NU author(s): Professor Graham Jackson, Professor Marcus Kaiser

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Abstract

© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within 12 months of autologous stem cell transplant was associated with markedly worse median progression-free survival 2 (PFS2) of 18 months and overall survival (OS) of 26 months, compared to median PFS2 of 85 months and OS of 91 months for later relapsing patients despite equal access to and use of subsequent therapies, highlighting the urgent need for improved outcome prediction and early intervention strategies for myeloma patients.

Publication metadata

Author(s): Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, Jenner M, Cook G, Drayson M, Owen R, Gregory W, Morgan G, Jackson G, Kaiser M

Publication type: Article

Publication status: Published

Journal: British Journal of Haematology

Year: 2021

Volume: 193

Issue: 3

Pages: 551-555

Print publication date: 01/05/2021

Online publication date: 10/06/2020

Acceptance date: 05/05/2020

Date deposited: 26/06/2020

ISSN (print): 0007-1048

ISSN (electronic): 1365-2141

Publisher: John Wiley & Sons Ltd

URL: https://doi.org/10.1111/bjh.16793

DOI: 10.1111/bjh.16793

Altmetrics

Share